Annexon Biosciences

Executive Summary

Annexon Biosciences is a clinical-stage biotechnology company pioneering therapies that inhibit C1q, the initiating protein of the classical complement pathway. The company aims to address devastating autoimmune, neurodegenerative, and ophthalmic diseases, including Guillain-Barré syndrome (GBS), geographic atrophy (GA), and Huntington's disease. By blocking C1q at the start of the complement cascade, Annexon's approach may preserve the protective functions of the alternative and lectin pathways while preventing complement-mediated damage. The company has advanced its lead candidate, ANX005, into late-stage clinical trials for GBS, with potential to become a first-in-class therapy. While the valuation (~$883M) reflects significant promise, the company faces typical development risks and competition from other complement inhibitors. The upcoming catalysts and clinical data readouts will be critical for determining the therapeutic potential and commercial opportunity of Annexon's pipeline.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for ANX005 in Guillain-Barré syndrome60% success
• Q2 2026Phase 2 data readout for ANX007 in geographic atrophy50% success
• Q4 2026Regulatory update for ANX005 in GBS (e.g., BLA submission or FDA meeting)70% success